Search Result

Results for "

B16F10

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Adrenergic Receptor (1) Akt (1) Apoptosis (10) Arginase (1) Bacterial (2) Bcl-2 Family (1) BCRP (1) c-Kit (2) c-Met/HGFR (2) Caspase (3) CDK (2) Dihydroorotate Dehydrogenase (1) Elastase (1) Endogenous Metabolite (2) Epigenetic Reader Domain (1) ERK (1) Ferroptosis (1) FGFR (1) FLT3 (2) Fluorescent Dye (1) HDAC (2) Interleukin Related (2) Isotope-Labeled Compounds (1) JAK (1) Liposome (1) MDM-2/p53 (1) Melanocortin Receptor (3) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Monoamine Oxidase (1) MyD88 (1) Necroptosis (1) NF-κB (1) NO Synthase (1) Parasite (1) PARP (1) PD-1/PD-L1 (2) Phosphatase (2) Phosphodiesterase (PDE) (1) PI3K (1) PROTACs (1) Raf (1) Ras (1) Reactive Oxygen Species (1) ROR (1) TAM Receptor (2) Toll-like Receptor (TLR) (1) Tyrosinase (6) VEGFR (4)
By Research Areas:	Cancer (44) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (7) Metabolic Disease (4) Neurological Disease (1)

By Targets:

ADC Cytotoxin (1)

Adrenergic Receptor (1)

Akt (1)

Apoptosis (10)

Arginase (1)

Bacterial (2)

Bcl-2 Family (1)

BCRP (1)

c-Kit (2)

c-Met/HGFR (2)

Caspase (3)

CDK (2)

Dihydroorotate Dehydrogenase (1)

Elastase (1)

Endogenous Metabolite (2)

Epigenetic Reader Domain (1)

ERK (1)

Ferroptosis (1)

FGFR (1)

FLT3 (2)

Fluorescent Dye (1)

HDAC (2)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

JAK (1)

Liposome (1)

MDM-2/p53 (1)

Melanocortin Receptor (3)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Monoamine Oxidase (1)

MyD88 (1)

Necroptosis (1)

NF-κB (1)

NO Synthase (1)

Parasite (1)

PARP (1)

PD-1/PD-L1 (2)

Phosphatase (2)

Phosphodiesterase (PDE) (1)

PI3K (1)

PROTACs (1)

Raf (1)

Ras (1)

Reactive Oxygen Species (1)

ROR (1)

TAM Receptor (2)

Toll-like Receptor (TLR) (1)

Tyrosinase (6)

VEGFR (4)

By Research Areas:

Cancer (44)

Cardiovascular Disease (2)

Infection (2)

Inflammation/Immunology (7)

Metabolic Disease (4)

Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W004288

Methyl myristate	Others	Cancer
Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma .

HY-N7587

Chlorophorin	Melanocortin Receptor	Metabolic Disease
Chlorophorin is a inhibitor of Melanocortin Receptor. Chlorophorin reduces tyrosinase activity and inhibits a-melanocyte-stimulating hormone-induced melanin production in B16F10 melanoma cells .

HY-160021

RORγt agonist 4	ROR	Inflammation/Immunology
RORγt agonist 4 (compound 14) is a potent and selective agonist of RORγt. RORγt agonist 4 significantly enhances metabolic stability. RORγt agonist 4 improves the situation of tumor models of mouse B16F10 melanoma and LLC lung adenocarcinoma .

HY-N9339

Norglaucine (+)-Norglaucine	Others	Cancer
Norglaucine ((+)-Norglaucine), a cytotoxic alkaloid, exhibits cytotoxicity towards the tumor cell lines B16-F10, HepG2, K562 and HL-60 cells .

HY-155681

SWS1	PD-1/PD-L1 Monoamine Oxidase	Cancer
SWS1 is a d-(+)-biotin-conjugated PD-L1 inhibitor (IC₅₀: 1.8 nM) with anticancer activity. SWS1 can increase the number of tumor-infiltrating lymphocytes and exhibit anti-tumor efficacy in the B16-F10 mouse model (TGI=66.1%) .

HY-P2336A

CCZ01048 TFA	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-156483

TT-012	Others	Cancer
TT-012 specifically binds to dynamic MITF and destroys the latter's dimer formation and DNA-binding ability. TT-012 inhibits the transcriptional activity of MITF in B16F10 melanoma cells. TT-012 inhibits the growth of high-MITF melanoma cells, and inhibits the tumor growth and metastasis with tolerable toxicity to liver and immune cells in animal models .

HY-149950

Anticancer agent 106	Apoptosis	Cancer
Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma .

HY-125762

Tyrosinase-IN-16	Tyrosinase	Cancer
Tyrosinase-IN-16 (compound 19a) is a tyrosine kinase (Tyrosinase) inhibitor with Ki=470 nM. Tyrosinase-IN-16 is cytotoxic to B16F10 cells, with >90% inhibition at 20 μM .

HY-P2336

CCZ01048	Melanocortin Receptor	Cancer
CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .

HY-157323

HDAC6-IN-28	HDAC Apoptosis	Cancer
HDAC6-IN-28 (compound 10C) is a potent inhibitor of HDAC6 with an IC₅₀ of 261 nM. HDAC6-IN-28 significantly induces apoptosis and S-phase arrest in B16-F10 cells. HDAC6-IN-28 efficiently increases the expression of acetylated-α-tubulin in vitro and in vivo .

HY-151509

A2-Iso5-2DC18	Others	Cancer
A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma. .

HY-W272217

Octacosane n-Octacosane; NSC 5549	Endogenous Metabolite Bacterial	Inflammation/Immunology Cancer
Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC₅₀ concentration of 7.2 mg/l .

HY-W004288S

Methyl tetradecanoate-d27 Myristic acid methyl ester-d₂₇	Isotope-Labeled Compounds	Cancer
Methyl tetradecanoate-d₂₇ is the deuterium labeled Methyl myristate. Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma[1].

HY-156092

Antitumor photosensitizer-4	BCRP Apoptosis	Cancer
Antitumor photosensitizer-4 (compound 10b) is a potent tyrosine kinase inhibitor (TKI) targeting ABCG2. Antitumor photosensitizer-4 is a photosensitizer (PS) consisting of a conjugate of dasatinib (HY-10181) and imatinib (HY-15463). Antitumor photosensitizer-4 induces apoptosis and ROS production and exhibits strong phototoxicity to HepG2 and B16-F10 cells .

HY-142955

Dual photoCORM 1	Others	Cancer
Dual photoCORM 1 (compound 5) is metal-free, photochemically active dual CORM. Dual photoCORM 1 exhibits good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach in cancerous B16F10 cells .

HY-W272217S

Octacosane-d58 n-Octacosane-d₅₈; NSC 5549-d₅₈	Bacterial Endogenous Metabolite
Octacosane-d₅₈ is the deuterium labeled Octacosane[1]. Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l[2][3][4].

HY-N3773

Dodoviscin A	Tyrosinase	Cancer
Dodoviscin A is a pigmentation-altering agent, which can be isolated from the aerial parts of Dodonaea viscosa. Dodoviscin A inhibits melanin production in B16-F10 melanoma cells. Dodoviscin A suppresses mushroom tyrosinase activity, and tyrosinase activity induced by 3-isobutyl-1-methylxanthine. Dodoviscin A also inhibits the phorphosylation of cAMP response element binding protein, induced by 3-isobutyl-1-methylxanthine and forskolin .

HY-156085

LP23	PD-1/PD-L1	Cancer
LP23 is a non-arylmethylamine PD-1/PD-L1 inhibitor (IC₅₀: 16.7 nM) with anti-tumor activity. LP23 restores immune cell function in HepG2/Jurkat T cells and promotes HepG2 cell death. LP23 is active in vivo in the B16-F10 tumor model (TGI=88.6% at 30 mg/kg) .

HY-155240

Tyrosinase-IN-13	Tyrosinase	Cancer
Tyrosinase-IN-13 (compound 3c), a derivative of Flurbiprofen (HY-10582), is a potent, non-competitive tyrosinase inhibitor (IC₅₀=68 μM; Ki=36.3 μM). Tyrosinase-IN-13 is cytotoxic against hepatocellular carcinoma (HepG2), colorectal cancer (HT-29), and melanoma (B16F10) .

HY-120241

Reticulol K 251-1	Phosphodiesterase (PDE)	Cancer
Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .

HY-149523

Anticancer agent 157	Apoptosis NO Synthase Caspase	Inflammation/Immunology Cancer
Anticancer agent 157 (compound 15) is a NO inhibitor (IC₅₀=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC₅₀=2.45 μg/mL), Hep-G2 liver cancer cells (IC₅₀=3.25 μg/mL), and B16-F10 murine melanoma cells (IC₅₀=3.84 μg/mL) .

HY-N10802

6-O-Isobutyrylbritannilactone	ERK Akt PI3K Epigenetic Reader Domain	Cancer
6-O-Isobutyrylbritannilactone is a natural melanogenesis inhibitor. 6-O-Isobutyrylbritannilactone, a sesquiterpene, can be isolated from the flowers of Inula britannica. 6-O-Isobutyrylbritannilactone inhibits IBMX (HY-12318)-induced melanin production in B16F10 cells. 6-O-Isobutyrylbritannilactone also regulates ERK, PI3K/AKT, and CREB, shows antimelanogenic activity in zebrafish embryos models .

HY-152263

HEMTAC CDK4/6 degrader 1	PROTACs CDK Apoptosis	Cancer
HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and CDK4/6 with a K_d value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests cell cycle at G0/G1 phase and induces apoptosis. HEMTAC CDK4/6 degrader 1 can be used in research of cancer . HEMTAC CDK4/6 degrader 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-146070

Elastase-IN-1

Elastase Inflammation/Immunology Cancer

Elastase-IN-1 (Compound Q11) is an elastase inhibitor with an IC₅₀ of 0.897 µM. Elastase-IN-1 is non-toxic .

Elastase-IN-1	Elastase	Inflammation/Immunology Cancer
Elastase-IN-1 (Compound Q11) is an elastase inhibitor with an IC₅₀ of 0.897 µM. Elastase-IN-1 is non-toxic .

HY-158021

Tyrosinase-IN-26	Tyrosinase	Cancer
Tyrosinase-IN-26 (compound 13) is a uncompetitive tyrosinase inhibitor with the an IC₅₀ value of 68.86 µM. Tyrosinase-IN-26 can suppresses melanogenesis .

HY-112476

PRL-3 Inhibitor I

Phosphatase Cancer

PRL-3 Inhibitor I is a potent PRL-3 inhibitor with an IC₅₀ of 0.9 μM. PRL-3 Inhibitor I shows a reduced invasion in cell-based assay .
HY-N11521

7-Methoxy obtusifolin

Tyrosinase Cancer

7-Methoxy obtusifolin (Compound 4) is a competitive tyrosinase inhibitor with an IC₅₀ of 7.0 μM .

PRL-3 Inhibitor I	Phosphatase	Cancer
PRL-3 Inhibitor I is a potent PRL-3 inhibitor with an IC₅₀ of 0.9 μM. PRL-3 Inhibitor I shows a reduced invasion in cell-based assay .

7-Methoxy obtusifolin	Tyrosinase	Cancer
7-Methoxy obtusifolin (Compound 4) is a competitive tyrosinase inhibitor with an IC₅₀ of 7.0 μM .

HY-153446

Tegeprotafib PTPN2/1-IN-1	Phosphatase	Cancer
Tegeprotafib (PTPN2/1-IN-1) (Compound 124) is an orally active PTPN1 and PTPN2 inhibitor with IC₅₀s of 4.4 nM and 1-10 nM against PTPN2 and PTP1B, respectively .

HY-13991A

(S)-CCG-1423	Ras	Metabolic Disease Cancer
(S)-CCG-1423 is an inhibitor of Rho signaling that blocks the nuclear import of MRTF-A. (S)-CCG-1423 reduces the nuclear accumulation of MRTF-A and improves glucose uptake and tolerance in insulin-resistance mice in vivo. (S)-CCG-1423 exhibits higher inhibition activity than the SR- and the R-isomers of CCG-1423 (HY-13991). (S)-CCG-1423 can be used for the research of cancer and diabetes .

HY-158027

B-Raf IN 17	Raf VEGFR FGFR	Cancer
B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of BRAF_WT, VEGFR-2, and FGFR-1 in A375 cell line, with IC₅₀ values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer .

HY-134954

Palmitoleoyl 3-carbacyclic phosphatidic acid	Others	Cancer
Palmitoleoyl 3-carbacyclic phosphatidic acid (3ccPA 16:1) is an intermediately potent inhibitor of autotaxin (ATX) with an IC₅₀ of 620 nM. Palmitoleoyl 3-carbacyclic phosphatidic acid can be used for melanoma research .

HY-155108

OATD-02	Arginase	Cancer
OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC₅₀s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study .

HY-13016

Cabozantinib Maximum Cited Publications 39 Publications Verification XL184; BMS-907351	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-19792

Mertansine 15+ Cited Publications DM1; Maytansinoid DM1	Microtubule/Tubulin ADC Cytotoxin	Cancer
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-136404

Melanin probe-1	Others	Cancer
Melanin probe-1 is an ¹⁸F-picolinamides based PET probe. Melanin probe-1 can be used for PET imaging of malignant melanoma. Melanin probe-1 exhibits high tumor targeting efficiency, excellent tumor imaging contrasts, desirable biodistribution patterns, and good in vivo stability .

HY-103211

L748337	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Cancer
L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over β1 and β2 receptors. The K_i values of L748337 for β3-, β2- and β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively . L748337 couples predominantly to G_i to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC₅₀ value of 11.6 . L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases .

HY-13016A

Cabozantinib hydrochloride XL184 hydrochloride; BMS-907351 hydrochloride	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib hydrochloride is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035 and 1.3 nM, respectively. Cabozantinib hydrochloride displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib hydrochloride shows antiangiogenic activity. Cabozantinib hydrochloride disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-149207

Tyrosinase-IN-11	Tyrosinase	Metabolic Disease
Tyrosinase-IN-11 is a potent tyrosinase inhibitor with IC₅₀s of 50 nM and 64 nM for L-tyrosinase and L-dopa, respectively. Tyrosinase-IN-11 has significant antioxidant activity and low cytotoxicity. Tyrosinase-IN-11 has the potential for skin hyperpigmentation research .

HY-148713

Anti-CSCs agent-1	Apoptosis	Cancer
Anti-CSCs agent-1 is a potent anti-CSCs agent. Anti-CSCs agent-1 inhibits cell growth and cell migration. Anti-CSCs agent-1 induces Apoptosis. Anti-CSCs agent-1 inhibits the viability of CSCs. Anti-CSCs agent-1 enhances the production of ROS in CSCs. Anti-CSCs agent-1 shows antitumor activity .

HY-158023

DHODH-IN-26	Dihydroorotate Dehydrogenase Reactive Oxygen Species Ferroptosis	Cancer
DHODH-IN-26 (compound B2) is a mitochondria-targeting DHODH inhibitor. DHODH-IN-26 shows anticancer activity, triggers the formation of reactive oxygen species (ROS), promots mitochondrial lipid peroxidation, and induces ferroptosis .

HY-153339

E235	Others	Cancer
E235 is an expression regulator of activates transcription factor 4 (ATF4). E235 reduces cell viability by activating integrated stress response (ISR) and DNA damage response signals. E235 has anti-proliferative activity and can be used for tumor research .

HY-146046

Antitumor agent-56	Apoptosis	Inflammation/Immunology Cancer
Antitumor agent-56 (Compound 33) is a triptolide derivative with antitumor, anti-inflammatory and NO release activities. Antitumor agent-56 significantly inhibits the growth of melanoma. Antitumor agent-56 is orally active .

HY-13594

Chlorin e6 5 Publications Verification Ce6	Bcl-2 Family Caspase PARP Apoptosis Fluorescent Dye	Infection Cancer
Chlorin e6 is a photosensitizer and has strong absorption peaks at wavelength of 402 and 662 nm, as well as exhibiting intense fluorescence at 668 nm. Chlorin e6 has antimicrobial efficacy and anticancer activity. Chlorin e6 induces cell apoptosis via caspase-3 activation and can be used for the research of cancer .

HY-116107

AG311

Necroptosis Cancer

AG311 is an anticancer and antimetastatic agent. AG311 induces rapid necrosis in numerous cancer cell lines .

AG311	Necroptosis	Cancer
AG311 is an anticancer and antimetastatic agent. AG311 induces rapid necrosis in numerous cancer cell lines .

HY-18976

UF010 2 Publications Verification	JAK HDAC NF-κB Toll-like Receptor (TLR) MyD88 Interleukin Related	Neurological Disease Inflammation/Immunology Cancer
UF010 is a selective inhibitor of class I HDAC. UF010 has cytotoxicity to cancer cells and reduces neuroinflammation in the hippocampus. UF010 can be used for the research of neurological diseases .

HY-B0263

Thiabendazole 1 Publications Verification Tiabendazole; 2-(4-Thiazolyl)benzimidazole	Mitochondrial Metabolism Parasite CDK MDM-2/p53 Others Caspase VEGFR Interleukin Related	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Thiabendazole is an orally available benzimidazole fungicide with repellent and anticancer activities. Thiabendazole can result in developmental malformations. Thiabendazole can be used for modeling .

HY-151506

Phospholipid PL1	Liposome	Cancer
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .

Cat. No.	Product Name	Category	Target	Chemical Structure